24小时热门版块排行榜    

查看: 625  |  回复: 3
本帖产生 1 个 翻译EPI ,点击这里进行查看

霜叶

金虫 (小有名气)

[求助] 翻译一段摘要,谢谢

OBJECTIVES:
Some large population-based studies have reported a dose-related increased risk of cataracts and glaucoma associated with use of inhaled corticosteroids (ICS) in patients with asthma or chronic obstructive pulmonary disease (COPD). We evaluated the association between use of ICS-containing products, specifically fluticasone propionate/salmeterol fixed-dose combination (FSC), and incidence of cataracts and glaucoma among patients with COPD in a large electronic medical record database in the United Kingdom.
METHODS:
We identified a cohort of patients aged 45 years and over with COPD in the General Practice Research Database (GPRD) between 2003 and 2006. Cases of incident cataracts or glaucoma were defined based on diagnosis and procedure codes and matched to controls from the risk set to estimate odds ratios (OR) and 95% confidence intervals (CI). The association with FSC or ICS exposure was modeled using conditional logistic regression. Medication exposure was assessed with respect to recency, duration, and number of prescriptions prior to the index date. Average daily dose was defined as none, low (1-250 mcg), medium (251-500 mcg), high (501-1000 mcg), or very high (1001+ mcg) using fluticasone propionate (FP) equivalents.
RESULTS:
We identified 2941 incident cataract cases and 327 incident glaucoma cases in the COPD cohort (n = 53,191). FSC or ICS prescriptions were not associated with risk of incident cataracts or glaucoma for any exposure category, after adjusting for confounders. We observed a lack of a dose response in all analyses, where low dose was the reference group. The odds of cataracts associated with FSC dose were medium OR: 1.1 (95% CI: 0.9-1.4); high OR: 1.2 (95% CI: 0.9-1.5); and very high OR: 1.2 (95% CI: 0.9-1.7). The odds of glaucoma associated with FSC dose: medium OR: 1.0 (95% CI: 0.5-2.1); high OR: 1.0 (95% CI: 0.5-2.0); and very high OR: 1.0 (95% CI: 0.4-2.8).
CONCLUSIONS:
FSC or other ICS exposure was not associated with an increased odds of cataracts or glaucoma, nor was a dose-response relationship observed in this population-based nested case-control study of COPD patients in the United Kingdom.
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

houbingxiao

木虫 (小有名气)

【答案】应助回帖

楼主你可以考虑多给点金子来吸引有才之士~~~~
Thesungoesdown,thestarscomeout,myuniversewillneverbethesame
2楼2013-03-26 15:43:16
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

vigor222

禁虫 (文坛精英)

本帖内容被屏蔽

3楼2013-03-26 15:51:34
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

Rio2016

木虫 (小有名气)

【答案】应助回帖

★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★
霜叶: 金币+15, 翻译EPI+1, ★★★★★最佳答案, 非常感谢,剩余的麻烦帮我再翻译,谢谢啦 我已追加金币 2013-03-26 18:15:44
霜叶(phu_grassman代发): 金币+10 2013-04-14 09:52:13
OBJECTIVES:
目标:
Some large population-based studies have reported a dose-related increased risk of cataracts and glaucoma associated with use of inhaled corticosteroids (ICS) in patients with asthma or chronic obstructive pulmonary disease (COPD).
We evaluated the association between use of ICS-containing products, specifically fluticasone propionate/salmeterol fixed-dose combination (FSC), and incidence of cataracts and glaucoma among patients with COPD in a large electronic medical record database in the United Kingdom. 一些基于大量人群的研究报告称,在患有哮喘或慢性阻塞性肺疾病(COPD)的病人发生白内障和青光眼的风险,与他们使用吸入式糖皮质激素(ICS)存在剂量递增性。我们评估了使用含吸入式糖皮质激素(ICS)产品,特别是丙酸氟替卡松/沙美特罗定量组合(FSC),与大英帝国一个大型电子医疗记录数据库中慢性阻塞性肺病患者 白内障和青光眼发生率的关系。

METHODS:
方法:
We identified a cohort of patients aged 45 years and over with COPD in the General Practice Research Database (GPRD) between 2003 and 2006.
Cases of incident cataracts or glaucoma were defined based on diagnosis and procedure codes and matched to controls from the risk set to estimate odds ratios (OR) and 95% confidence intervals (CI). 在研究数据库(GPRD)中处于2003到2006年这段期间里,我们发现了一个年龄为45岁且患有COPD的同期组群。白内障或青光眼的发生病例通过诊断和程序编码来确定,并结合通过控制风险设定来计算比值比(OR)和置信区间为95%。




先这么多吧 、、确实不好翻译
寥寥数年、将就过活
4楼2013-03-26 17:10:46
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖
相关版块跳转 我要订阅楼主 霜叶 的主题更新
信息提示
请填处理意见